Endocrinol Metab > Volume 22(3); 2007 > Article
Journal of Korean Endocrine Society 2007;22(3):229-234.
DOI: https://doi.org/10.3803/jkes.2007.22.3.229    Published online June 1, 2007.
Amiodarone Induced Thyrotoxicosis (Type II).
Cho Young Ju, Hearn Kook Kim, Hyoung Jung Chung, Yong Jin Park, Jin Yeob Kim, Seung Mun Jung, Su Jung Choi, Gil Hyun Kang, Myoung Sook Shim
1Department of Internal Medicine, University of Ulsan, Gangneung Asan Hospital, Korea.
2Department of Diagnostic Radiology, University of Ulsan, Gangneung Asan Hospital, Korea.
3Department of Pathology, University of Ulsan, Gangneung Asan Hospital, Korea.
Amiodarone is an iodinated benzofuran derivative, that is highly effective as an agent for the treatment of various cardiac arrhythmias; these arrthymias, range from paroxysmal atrial fibrillation to life-threatening ventricular tachyarrhythmias. Yet amiodarone is associated with several side effects that include dysfunction of liver, thyroid or various other organs. Two main forms of amiodarone induced thyrotoxicosis (AIT) have been described; type I AIT develops in an abnormal thyroid gland (nodular goiter, latent Graves' disease) and it is due to amiodarone-induced true hyperthyroidism; type II AIT occurs in an apparently normal thyroid gland and it is due to amiodarone-induced destructive thyroiditis. We recently experienced a case of type II thyrotoxicosis that was induced by amiodarone treatment for ventricular tachycardia after acute myocardial infarction. The symptoms of thyrotoxicosis were relieved after withdrawal of amiodarone and administering steroid. Type I AIT has often been reported on but type II AIT is relatively rare. We report here on a case of type II amiodarone induced thyrotoxicosis along with a literature review.
Key Words: Amiodarone, Amiodarone induced thyrotoxicosis, Hyperthyroidism

Editorial Office
101-2503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-716-2428    Fax: +82-2-714-5103    E-mail: journal@endocrinology.or.kr                

Copyright © 2022 by Korean Endocrine Society.

Developed in M2PI